
Prudencio M Tossou
@TOSSOUPrudencio
Followers
381
Following
386
Media
1
Statuses
116
Co-founder of @valence_ai. Research: OOD + low data + drug discovery. Host of the M2D2 Talk Series. https://t.co/KMFRms1Wtw
Joined January 2012
RT @valence_ai: 1/ At Valence Labs, @RecursionPharma's AI research engine, we’re focused on advancing drug discovery outcomes through cutti….
0
20
0
RT @hsu_jonny: Excited to welcome @DrAnneCarpenter to Montreal to start week 2 of the ML for drug discovery summer school with an overview….
0
4
0
RT @_portal_: Day 1 of the ML for Drug Discovery Summer School was awesome! 🏫. Over 150 people were in attendance to learn from speakers li….
0
5
0
RT @cas_wognum: I am excited to present Polaris @pydatalondon!✨. I look forward to share more about the benchmarking platform we are buildi….
0
9
0
RT @hsu_jonny: Looking forward to #MoML2024 on June 19th! . As always, tickets for students are FREE. Join us @Mila_Quebec for an awesome….
portal.ml4dd.com
Tickets for the summer school & MoML 2024
0
2
0
To learn about the SOTA in batch effect removal in biochemical data, join us next Tuesday from 11am - 12pm ET.
Next week at M2D2, @ChenyuW64562111 will present “Removing Biases from Molecular Representations via Information Maximization”. 📅 When: Tuesday from 11am - 12pm ET. 📝 Read the paper: Tune in live:
0
0
5
RT @hsu_jonny: Tune in to the latest reading groups, read blogs, and connect with the TechBio community on @_portal_. We also provide weekl….
0
1
0
RT @_portal_: Next week at M2D2, @SusanaVazTor will present “De novo design of high-affinity binders of bioactive helical peptides”. 📅 When….
portal.valencelabs.com
In this presentation, I will discuss our recent study focused on the de novo design of protein binders targeting helical peptides. Our research integrates traditional and deep learning molecular ...
0
2
0
RT @valence_ai: Introducing LOWE: an LLM-Orchestrated Workflow Engine for executing complex drug discovery workflows using natural language….
0
22
0
RT @valence_ai: That’s a wrap on #NeurIPS 2023. From cohosting a 700+ person TechBio event with @RecursionPharma and @NVIDIA to showcasing….
0
15
0
RT @valence_ai: Introducing SAFE, Sequential Attachment-based Fragment Embedding, a novel molecular line notation that redefines molecular….
0
34
0
RT @datamol_io: Catch @ENoutahi @craigmichaelm @TOSSOUPrudencio @jonathanlimsc at #NeurIPS tomorrow! . They'll be presenting the SAFE paper….
0
4
0
RT @valence_ai: In the latest community blog, @JeffGuo__ from @SchwallerGroup describes how experience replay can accelerate generative mol….
portal.valencelabs.com
Generative drug design has moved from a proof-of-concept paradigm to real-world impact as observed in the recent surge in works reporting experimental validation (verified binding in cell assays) for...
0
11
0
RT @valence_ai: Next week at M2D2, we’ll be joined by @HannesStaerk who will discuss his recent paper “Harmonic Self-Conditioned Flow Match….
portal.valencelabs.com
Abstract: A significant amount of protein function requires binding small molecules, including enzymatic catalysis. As such, designing binding pockets for small molecules has several impactful ...
0
7
0
RT @valence_ai: M2D2 is back!. We’ll be joined by Prof. @AmirBaratiF from @CarnegieMellon who will discuss his recent work in large languag….
portal.valencelabs.com
Talk Abstract: Molecular machine learning shows significant potential for enhancing molecular property prediction and drug discovery. Nevertheless, obtaining labelled molecule data can prove to be a...
0
10
0
RT @valence_ai: Today we begin our new journey as Valence Labs: a semi-autonomous research engine within @RecursionPharma, dedicated to adv….
0
23
0
RT @valence_ai: As part of our meetup at #ICML2023 on Wednesday, we’ll be hosting a panel with @cuong_qnguyen (@gsk), Alan Cheng (@merck),….
0
16
0
RT @valence_ai: We are incredibly excited to integrate our powerful chemistry engine into @RecursionPharma’s OS to enable the future of AI-….
0
19
0
RT @valence_ai: This week at M2D2, @YunchaoLanceLiu presented MolKGNN, an interpretable and chirality-aware GNN with improved performance….
0
1
0